=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:18:25 ON 29 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 AUG 2006 HIGHEST RN 904961-01-9
DICTIONARY FILE UPDATES: 28 AUG 2006 HIGHEST RN 904961-01-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10809636gt.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S
G2 CH2,CH,A,Ak
G3 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:18:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    16091 TO ITERATE

 12.4% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       314223 TO   329417
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:18:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   321692 TO ITERATE

100.0% PROCESSED   321692 ITERATIONS                                32 ANSWERS
SEARCH TIME: 00.00.10

L3           32 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'CAPLUS' ENTERED AT 15:19:06 ON 29 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Aug 2006  VOL 145 ISS 10
FILE LAST UPDATED: 28 Aug 2006  (20060828/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            7 L3
```

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:247321 CAPLUS
DOCUMENT NUMBER: 134:280852
TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023365	A1	20010405	WO 2000-EP8940	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385921	AA	20010405	CA 2000-2385921	20000913
BR 2000014294	A	20020521	BR 2000-14294	20000913
EP 1216235	A1	20020626	EP 2000-965991	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6890930	B1	20050510	US 2002-89166	20000913
NO 2002001502	A	20020326	NO 2002-1502	20020326

PRIORITY APPLN. INFO.:		
US 1999-407958	A	19990928
US 1999-287586P	P	19990928
WO 2000-EP8940	W	20000913

OTHER SOURCE(S): MARPAT 134:280852
GI



I



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; Z = bond, phenylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n = 1-3; m = 0-3; with a variety of provisos]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, 3-(aminomethyl)benzylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.

IT 332363-12-9P, 3-(3-Aminomethylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one
332363-13-0P, 3-(3-Aminomethylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate)

RN 332363-12-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 332363-13-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:247320 CAPLUS
DOCUMENT NUMBER: 134:280851
TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023364	A1	20010405	WO 2000-EP8939	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2385918	AA	20010405	CA 2000-2385918		20000913
BR 2000014311	A	20020521	BR 2000-14311		20000913
EP 1216233	A1	20020626	EP 2000-962482		20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
NO 2002001503	A	20020326	NO 2002-1503		20020326
US 7060706	B1	20060613	US 2002-89167		20020829
PRIORITY APPLN. INFO.:			US 1999-407939	A	19990928
			US 1999-325777P	P	19990928
			WO 2000-EP8939	W	20000913

OTHER SOURCE(S): MARPAT 134:280851
GI



I



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n, m = 0-3]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, [[3-(aminomethyl)cyclohexyl]methyl]amine , was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant

dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.

IT 332121-76-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one
332121-77-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-methyl-3H-quinazolin-4-one
332121-78-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one
332121-79-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-methoxy-3H-quinazolin-4-one
332121-80-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as glycoprotein IbIX antagonists)

RN 332121-76-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)





RN 332121-77-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-methyl- (9CI) (CA INDEX NAME)





RN 332121-78-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 332121-79-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-methoxy- (9CI) (CA INDEX NAME)



RN 332121-80-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:12269 CAPLUS

DOCUMENT NUMBER: 124:175225
TITLE: Electron impact-promoted fragmentation of some substituted 4-quinazolones
AUTHOR(S): Badr, M. Z. A.; Hammerum, Steen; Duffield, A. M.
CORPORATE SOURCE: Chemistry Department, Assiut Univ., Assiut, Egypt
SOURCE: Journal of Mass Spectrometry (1995), 30(12), 1701-6
CODEN: JMSPFJ; ISSN: 1076-5174
PUBLISHER: Wiley
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Low-resolution mass spectra, and where appropriate complete high-resolution spectra, were recorded for 29 2,3-disubstituted 4-quinazolones. Rationalizations are presented for the principal fragmentation modes of this series of aromatic compds. Four of the 4-quinazolones which contain a vinyl-2-furanyl group attached to C-2 of the heterocyclic ring exhibited an unusual loss of C3H2O from their resp. mol. ions.

IT 56479-05-1
RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(electron impact-promoted fragmentation of substituted 4-quinazolones)

RN 56479-05-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:143365 CAPLUS
DOCUMENT NUMBER: 98:143365
TITLE: Synthesis and antiparkinsonian activity of styryl quinazolones
AUTHOR(S): Kumar, Pradeep; Nath, C.; Bhargava, K. P.; Shanker, K.
CORPORATE SOURCE: Dep. Pharmacol. Therapeut., King George's Med. Coll., Lucknow, 226003, India
SOURCE: Pharmazie (1982), 37(11), 802
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB Condensation of acetanthranils I (R = H, Br, iodo; R1 = H, Br) with R2C6H4NHNH2 (R2 = H, 2-Me, 4-NO2) gave methylquinazolines II, which condensed with benzaldehydes to give styrylquinazolines III (R3 = 4-MeO, 4-NO2, Me2N, 3-NO2, 2-Cl, 2-F, R4 = H; R3 = 3-Me, R4 = 4-HO; R3R4 = CH2O2). Antiparkinsonian activities of III at 100 mg/kg in rats were tested against oxotremorine induced tremors and reserpine induced rigidity. III (R = R1 = R2 = R3 = H, R4 = 4-MeO; R = Br, R1 = R2 = R3 = H, R4 = 2-Cl) possessed maximum activity with a tremor index of 2.4 (control 3.0) and 20% rigidity (control 100%).

IT 85226-44-4P 85226-45-5P 85226-47-7P
85226-48-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiparkinsonian activity of)

RN 85226-44-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-3-(phenylamino)- (9CI) (CA INDEX NAME)



RN 85226-45-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-3-[(4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RN 85226-47-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-iodo-3-[(4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RN 85226-48-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-iodo-3-[(2-methylphenyl)amino]-2-[2-(3-nitrophenyl)ethenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1979:611313 CAPLUS
DOCUMENT NUMBER: 91:211313
TITLE: Studies on the synthesis of 2,3-disubstituted 4(3H)quinazolinone
AUTHOR(S): Badr, M. Z. A.; El-Sherif, H. A. H.
CORPORATE SOURCE: Fac. Sci., Univ. Assiut, Assiut, Egypt
SOURCE: Egyptian Journal of Chemistry (1978), Volume Date 1976, 19(2), 341-6
CODEN: EGJCA3; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Quinazolinone derivs. (I; R = Et, Ph, PhCH2; R1 = aryl, 2-furyl) were prepared in 80-90% yields by Knoevenagel condensation of II with R1CHO in

absolute EtOH containing EtONa.

IT 56479-05-1P 71822-48-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56479-05-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 71822-48-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(3-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:497193 CAPLUS
DOCUMENT NUMBER: 83:97193
TITLE: Synthesis of some benzoxazin-4-ones, quinazolin-4-ones, and the related products
AUTHOR(S): Messiha, N. N.; Abdel-Kader, A. M. M.; Nosseir, M. H.
CORPORATE SOURCE: Lab. Polym. Pigm., Natl. Res. Cent., Cairo, Egypt
SOURCE: Indian Journal of Chemistry (1975), 13(4), 326-8
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 83:97193
GI For diagram(s), see printed CA Issue.
AB Benzoxazinones I [R = 2-furyl, p-Me2NC6H4, 3,4-(MeO)(HO)C6H3] prepared by condensation of 2-methyl-3,1-benzoxazin-4-one with RCHO, were cleaned with R1NH2 to give o-R1NHCOC6H4NHCOCH:CHR (II, R1 = Me, Et, Bu, PhCH2, NH2; R1 = same as above). Styrylquinazolinones III were prepared by condensation of 2-methyl-3-alkylquinazolin-4-ones with RCHO. III prepared were [R =

3,4-(MeO)(HO)C6H3, R1 = Me, Et; R = 2-furyl, R1 = Me, PhCH2]. Treatment of I with NaN gave tetrazoles IV [R = 2-furyl, p-tolyl, 3,4-(MeO)(HO)C6H3] and benzimidazoles V (R = same as above, p-Me2NC6H4). II treated with NaNO2 gave (o-RCH:CHCONHC6H4NH)2CO [R = p-tolyl, 3,4-(MeO)(HO)C6H3]. Infrared studies indicated trans-olefin in these products. Uv showed that substituents caused a bathochromic shift increasing in the order p-Me<p-Cl<p-MeO<3,4-(MeO)(HO)<p-Me2N.

IT 56479-05-1 56479-06-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(spectral characteristics of)

RN 56479-05-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 56479-06-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-[2-(2-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1974:3464 CAPLUS
DOCUMENT NUMBER:	80:3464
TITLE:	Action of Grignard reagents and aryllithium on 3-alkyl-2-styrylquinazol-in-4-ones and 2-styryl-3,1-benzoxazin-4-ones
AUTHOR(S):	Messiha, N. N.; Doss, N. L.; Nosseir, M. H.
CORPORATE SOURCE:	Lab. Polym. Pigm., Natl. Res. Cent., Cairo, Egypt
SOURCE:	Indian Journal of Chemistry (1973), 11(8), 738-40 CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE:	Journal
LANGUAGE:	English

GI For diagram(s), see printed CA Issue.

AB Some derivs. of 2-styryl-3,1-benzoxazin-4-ones (I) and 3-alkyl-2-styrylquinazolin-4-ones (II) were prepared by reaction of the corresponding aldehyde with the ketone. 3-Alkyl- and 3-amino-2-styrylquinazol-4-ones react sep. with arylmagnesium halides (3 mole equivalent) to give 3-alkyl- and 3-amino-2-(α,α'-diarylethyl)quinazolin-4-ones, resp. With aryllithium, I and II gave o-(cinnamoylamidophenyl)diarylcarbinols and 3-alkyl-4,4'-diaryl-2-styrylquinazolines, resp. Structures were assigned on the basis of anal. ir, and uv spectral data.

IT 50830-12-1P 50830-16-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 50830-12-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 50830-16-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(2-nitrophenyl)ethenyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.23	203.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.25	-5.25

STN INTERNATIONAL LOGOFF AT 15:19:26 ON 29 AUG 2006